Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
May 23, 2019 8:30 AM EDT
20ᵀᴴ Annual B. Riley FBR Institutional Investor Conference
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will participate in a fireside chat presentation with Mayank Mamtani, B. Riley FBR research analyst
Beverly Hills
Archived Events
Date Event Details
Aug 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Third Quarter Results
May 5, 2017 11:30 AM CDT
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017 Scientific Sessions

Location: Minneapolis, MN

Title: Factor 12 RNAi-based therapeutic as a prophylactic anti-thrombotic therapy

May 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Second Quarter Results
Apr 19 - Apr 23, 2017 12:00 AM EDT
The EASL International Liver Congress™ 2017
Amsterdam, The Netherlands

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

  • Presentation Reference: PS-045
  • Session: Parallel session: Hepatitis B and D: Emerging treatment options
  • Date and Time: April 20, 2017 at 5:30 PM CET
  • Authors: Man-Fung Yuen, et al.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

  • Presentation Reference: THU-176
  • Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
  • Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
  • Authors: Edward Gane, et al.

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients

  • Presentation Reference: LBO-06
  • Session: Late Breaker session
  • Date and Time: April 22, 2017 at 5:15 PM CET
  • Authors: Alice Turner, et al.
Feb 21 - Feb 23, 2017 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 6, 2017 4:30 PM EST
Arrowhead Fiscal 2017 First Quarter Results
Dec 14, 2016 4:30 PM EST
Arrowhead Fiscal 2016 Year End Results
Nov 30, 2016 8:30 AM EST
The 28th Annual Piper Jaffray Healthcare Conference
New York

November 30, 8:30 a.m. EST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray.

Presentation Canceled

Nov 29, 2016 4:30 PM EST
Clinical Update Call
Nov 14, 2016 10:00 AM CST
American Heart Association's Scientific Sessions 2016
New Orleans

November 14, 10:40 a.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism”

November 14, 2:00 p.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)”